Education
About Us
Working with TipRanks
Follow Us
Effector Therapeutics, Inc. (EFTR)
:EFTR
RESEARCH TOOLSreports
EFTR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $16.88
Previous CloseN/A
Volume10.00
Average Volume (3M)38.30K
Market Cap
$2.82K
Enterprise ValueN/A
Total Cash (Recent Filing)-$3.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-88.04
Next Earnings
May 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.31
Shares Outstanding4,704,409
10 Day Avg. Volume22,048
30 Day Avg. Volume38,305
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
eFFECTOR Therapeutics News
---
Ownership Overview
5.43% Insiders
<0.01% Mutual Funds
1.31% Other Institutional Investors
93.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EFTR FAQ
What was Effector Therapeutics, Inc.’s price range in the past 12 months?
Effector Therapeutics, Inc. lowest stock price was $0.03 and its highest was $16.88 in the past 12 months.
What is Effector Therapeutics, Inc.’s market cap?
Effector Therapeutics, Inc.’s market cap is $2.82K.
When is Effector Therapeutics, Inc.’s upcoming earnings report date?
Effector Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 48 days.
How were Effector Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Effector Therapeutics, Inc. overvalued?
According to Wall Street analysts Effector Therapeutics, Inc.’s price is currently Overvalued.
Does Effector Therapeutics, Inc. pay dividends?
Effector Therapeutics, Inc. does not currently pay dividends.
What is Effector Therapeutics, Inc.’s EPS estimate?
Effector Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Effector Therapeutics, Inc. have?
Effector Therapeutics, Inc. has 4,704,409 shares outstanding.
What happened to Effector Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Effector Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EFTR
---
Company Description
Effector Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
---
EFTR Stock 12 Month Forecast
Average Price Target
―Fate Therapeutics
―
Karyopharm Therapeutics
―
Arcutis Biotherapeutics
―
Immatics
―
Foghorn Therapeutics
―
Best Analysts Covering EFTR
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-80.00%
reiterated a buy rating 11 months ago
Copying Benjamin Burnett's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -80.00% per trade.
---